Suptavumab
Monoclonal antibody
Type?
SourceHuman
Targetrespiratory syncytial virus fusion protein
Clinical data
Other namesREGN2222
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6502H10038N1726O2020S42
Molar mass146054.41 g·mol−1

Suptavumab (INN;[1] development code (REGN2222) is a humanized monoclonal antibody designed for the prevention of medically attended lower respiratory tract disease due to respiratory syncytial virus.

This experimental drug candidate was being developed by Regeneron Pharmaceuticals Inc until it was discontinued after unsuccessful Phase III clinical trials.[2][3]

References

  1. ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Suptavumab, American Medical Association.
  3. ^ "Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus" (Press release). Regeneron. August 14, 2017.


Categories